Canada markets closed
  • S&P/TSX

    19,203.70
    +2.42 (+0.01%)
     
  • S&P 500

    4,141.59
    +13.60 (+0.33%)
     
  • DOW

    33,677.27
    -68.13 (-0.20%)
     
  • CAD/USD

    0.7976
    -0.0005 (-0.06%)
     
  • CRUDE OIL

    60.55
    +0.37 (+0.61%)
     
  • BTC-CAD

    79,540.98
    +3,899.93 (+5.16%)
     
  • CMC Crypto 200

    1,353.54
    +59.55 (+4.60%)
     
  • GOLD FUTURES

    1,746.40
    -1.20 (-0.07%)
     
  • RUSSELL 2000

    2,228.92
    -4.86 (-0.22%)
     
  • 10-Yr Bond

    1.6230
    -0.0520 (-3.10%)
     
  • NASDAQ futures

    13,970.25
    -5.50 (-0.04%)
     
  • VOLATILITY

    16.65
    -0.26 (-1.54%)
     
  • FTSE

    6,890.49
    +1.37 (+0.02%)
     
  • NIKKEI 225

    29,751.61
    +212.88 (+0.72%)
     
  • CAD/EUR

    0.6672
    -0.0001 (-0.01%)
     

Aequus Closes $1 Million Financing

  • Oops!
    Something went wrong.
    Please try again later.
Aequus Pharmaceuticals
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES

VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products is pleased to announce that it has closed a non-brokered private placement of 6,666,666 units of the Company (the "Units") at a price of $0.15 per Unit (the "Offering Price"), for aggregate gross proceeds of $1,000,000 (the “Private Placement”) to Marc Lustig, a director of the Company. Each Unit shall consist of one common share of the Company and one-half non-transferrable common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant shall entitle the holder thereof to purchase one common share at an exercise price of $0.25 for a period of twenty-four (24) months following the transaction closing date. The Units will be subject to a four month hold period expiring June 27, 2021.
Aequus intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including commercial and marketing activities and supporting on-going business development.

The securities issued under the Private Placement will be subject to a four month hold period in Canada following the date of closing. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The issuance of Units to Mr. Lustig under the Private Placement constitutes a related-party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”). This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of any securities issued to, nor the consideration paid by, such individual would exceed 25.0% of the Company’s market capitalization.

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

Forward-Looking Statements

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: proposed use of proceeds of the Private Placement, the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launch; the Company’s expected revenues. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 28, 2020, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

Contact Information:

Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906